Category Archives: Regenerative Medicine

New Technology Investment in Age-Old Question: Regenerative Medicine

October 1, 2013 (www.investorideas.com newswire) Regenerative medicine is a field involving the study of stem cells to regenerate or regrow cells and even entire body parts in humans, reestablishing normal function. Successes in regenerative medicine could help the entire medical field advance as previously chronic and incurable conditions may be reversible. Some estimates claim that as many as 1 in 3 Americans would be helped by regenerative medicine therapies.

Stem cells function as "master cells," which have the ability to become any other type of cell. Natural stem cells can be found in human cord blood and embryos. Stem cells can also be created through a "reprogramming" process, using blood and skin cells to create induced pluripotent stem cells (iPS). Recently, scientists at the Spanish National Cancer Research Center in Madrid were able to replicate human stem cells in mice, opening a new avenue for regenerative medicine. These cells may possess more plasticity and may be better able to differentiate into many more types of adult human cells than traditional iPS cells.

According to a recent article in Forbes, regenerative medicine could take 20 to 25 years to truly come to fruition. However, some regenerative medicine therapies are being used today, such as implementing stem cell therapies to repair knee joint damage. Many small cap companies operate in the field, helping to fuel progress in regenerative medicine.

Osiris Therapeutics, Inc. (Nasdaq:OSIR), based in Columbia, MD, manufactures mesenchymal stem cells (MSCs), which are typically created from bone marrow donations. The rapidly-grown MSCs can then be frozen for future patient use. Because MSCs are "attracted" to the damaged or diseased area, the cells can be introduced into a patient? body through injection or intravenous methods. Osiris markets Prochymal, which was approved in Canada in May 2012. It is currently undergoing Phase III clinical trials in the US for acute graft versus host disease and Crohn? disease. OSIR closed September 30th at 16.64, up 0.15, with a market cap of 550.31 million. Its 52-week trading range is 6.55 - 27.40.

Rockville, MD-based Neuralstem, Inc. (NYSE:CUR) uses their patented technology to produce neural stem cells based on the human brain and spinal cord. They currently have three FDA-approved trials: a Phase II trial on their NSI-566 therapy for treatment of amyotrophic lateral sclerosis (ALS), a Phase I trial for the same therapy for chronic spinal cord injury and a Phase Ib trial of their NSI-189 therapy to treat major depressive disorder (MDD). By using stem cells derived from site-specific areas of the body, these cells may already be suited for the type of treatment they are expected to provide. CUR closed September 30th at 2.71, down 0.10, with a market cap of 192.74 million. Its 52-week trading range is 0.88 - 3.02.

One important element of stem cell research is the ability to preserve and store the cells until needed. BioLife Solutions, Inc. (OTCMKTS:BLFS), based in Bothell, WA, creates cGMP-grade bio-preservation media for blood, organs and cells, including stem cells. BioLife recently signed an agreement with SAVSU Technologies, Inc to market SAVSU? thermal packaging products. Temperature stability is a significant piece of the biologistics - the logistics of transporting cells and tissues - puzzle. BLFS closed September 30th at 0.795, no change for the day, with a market cap of 58.13 million. Its 52-week trading range is 0.13 - 0.88.

Health care investors interested in new opportunities in interesting sectors may wish to seek out small caps in the regenerative medicine arena. Although it may be some time before comprehensive regenerative medicine therapies are available on a widespread scale, these cutting-edge companies are making scientific advances that could become quite important. With breakthroughs in stem cell research and creation occurring frequently, investment in these new health technologies may well provide future growth.

The About Small Cap blog covers breaking news on small cap stocks from around the world, delving deep into pressing issues both large and small that affect small caps. For example, we recently covered groundbreaking news about artificial heart technology in the small cap world. We write about things like natural gas drilling and interviews with notable personalities across a wide variety of industries, like Elemer Piros in the biotech sector.

More Info:

View post:
New Technology Investment in Age-Old Question Regenerative Medicine

MARLBOROUGH, Mass.--(BUSINESS WIRE)--

Advanced Cell Technology, Inc. (ACT; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today that its chief scientific officer, Robert Lanza, M.D., will be delivering a Keynote lecture at the World Conference on Regenerative Medicine being held in Leipzig, Germany October 23-25th. The Conference is considered one of the world's largest and most influential events in stem cells and regenerative medicine, and provides a platform that brings scientists with an academic, clinical and industrial background together. Dr. Lanzas Lecture, entitled ES and iPS Cells Moving into the Clinic, will take place at 9:00 a.m. at the Congress Center Leipzig.

The World Conference will, as in past years, encompass a broad range of topics in regenerative medicine from biomaterials to biomarkers as well as regulation and stem cell technologies. The organizers expect more than 1,000 attendees and hundreds of papers with ground-breaking scientific insights and new results. Furthermore, the conference will host a large exhibition where international researchers and biotechnology companies can demonstrate the reach of current technologys translation and the implementation of research in products. In addition to Dr. Lanzas Keynote Lecture, the Conference will include presentations on cell and immunotherapy, stem cells, cell and tissue engineering, biomaterials and tissue interaction, models of regeneration, molecular mechanisms of regeneration, diagnostic and imaging of regeneration, and regulatory affairs.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, the relevance and applicability of clinical trials in animals to studying the effect of products in humans, future growth in animal and human research and development programs, potential new applications of and expanded indications covering our technology, the effects of donorless sources of stem cells on potency and the risk of communicable diseases in the manufacturing context, the existence and size of potential or existing market opportunities for the company, the effect of the companys products on the medical needs and quality of life of pets, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words will, believes, plans, anticipates, expects, estimates, and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for and limited sources of future capital, failures or delays in obtaining regulatory approval of products, risks inherent in the development and commercialization of potential products, reliance on new and unproven technology in the development of products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the companys periodic reports, including the Quarterly Report on Form 10-Q for the three months ended June 30, 2013. Forward-looking statements are based on the beliefs, opinions, and expectations of the companys management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the companys management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Companys clinical trials will be successful.

See original here:
ACT’s Dr. Robert Lanza to Deliver Keynote Lecture at the World Conference on Regenerative Medicine

OTTAWA, ONTARIO and TORONTO, ONTARIO--(Marketwired - Oct 21, 2013) - Stem cell and regenerative medicine experts from around the world will physically and virtually come together in Banff, Alberta, when Canada's premier stem cell research event - the Till & McCulloch Meetings (T&MM) - takes place October 23-25, 2013.

"Canada and Europe chose the same dates to host their most significant regenerative medicine events and we're utilizing technology to bring the two conferences together," explains Drew Lyall, Executive Director of the Stem Cell Network. "While our European colleagues won't get to enjoy the beauty of Alberta, they will benefit from hearing some thrilling science, produced in Canada."

A novel technology discovered in Dr. Peter Zandstra's lab, which has the potential to improve the viability and success of cord blood stem cell transplantation, will be featured during a live broadcast to the World Conference on Regenerative Medicine in Leipzig, Germany, on October 24 at 8:45 a.m. Dr. Zandstra (University of Toronto and CSO with the Centre for Commercialization of Regenerative Medicine) has received the 2013 Till & McCulloch Award for having published the year's most influential peer-reviewed article by a stem cell researcher in Canada.

Other highlights include the following:

October 23 at 12:20 p.m.

The conference will premiere and showcase a series of short, animated videos about basic concepts in stem cell research narrated by world-renowned stem cell scientists. The videos are produced by Ben Paylor, a PhD candidate in experimental medicine at the University of British Columbia, and Mike Long, a post-doctoral fellow at the University of Toronto, who engaged award-winning animator David Murowsky and Emmy-nominated composer James Wallace to create the signature animations and music featured in the videos. The three videos are targeted at youth of high school age or older. More details about the videos and the award can be found here: http://bit.ly/15GBOsw.

October 23 at 2:10 p.m.

An afternoon plenary session will focus on current research in cell therapy. The session will include presentations by Dr. Duncan Stewart (Ottawa Hospital Research Institute) on lessons learned in bringing cell therapies to the clinic. He will focus on his recently launched stem cell clinical trial for the treatment of acute heart attack, as well as offer overviews of Canada's strategy for stem cell research going forward and the emerging regenerative medicine technologies market.

"The regenerative medicine market is poised to experience explosive growth in the near future, based on the increasing number of clinical trials, deals, IPOs [initial public offerings] and partnerships happening globally," says Michael May, CEO of the Centre for Commercialization of Regenerative Medicine (CCRM). "Canada's leadership in the field of regenerative medicine is already well known, and it is with events and collaborations like the Till & McCulloch Meetings that we will continue to build a strong infrastructure for future growth in Canada. The fact that this year's conference has engaged 39 industry sponsors - more than twice the number that participated last time - is an indication of just how far we've progressed in a short time."

The Till & McCulloch Meetings, formerly the Stem Cell Network's Annual Scientific Meeting, was renamed in 2012 to acknowledge its expanded focus to include the broader field of regenerative medicine and the business focus of commercializing stem cell- and biomaterials-based products and therapies. In addition to excellent science originating from Canada, Japan, China, Israel, Europe and the United States, the conference will feature industry networking meetings and international efforts to share resources to accelerate progress in commercializing new discoveries.

Read the original post:
International Stem Cell and Regenerative Medicine Community Convenes in Banff, Alberta

LA JOLLA, CA--(Marketwired - Oct 14, 2013) - A comprehensive reimbursement guide for regenerative medicine was released today at the third annual Stem Cell Meeting on the Mesa Regen Med Partnering Forum. This guide was developed by the Alliance for Regenerative Medicine (ARM), an international organization representing the regenerative medicine community, and comprises a series of white papers designed to help regenerative medicine companies navigate the reimbursement process.

As with all therapies, regenerative medicine products will need to go through a rigorous evaluation and approval process to receive coverage and payment by public health plans and private insurance. This guide was developed to provide information on the coding, coverage and payment processes, as well as address some of the unique issues regenerative medicine therapies may face along the way. While not specific to any one type of regenerative medicine product, these briefs provide companies with early warnings about pitfalls that can be avoided with proper planning and action.

"We believe it is critical to design and implement a reimbursement strategy early in a product's development process, and this guide will offer valuable, timesaving assistance to companies in the regenerative medicine field," said Antonio Montecalvo, Director of Customer Support Services, Organogenesis Inc., and Chair of ARM's Reimbursement Committee. "The potential for regenerative medicine products to cure diseases is tremendous, and we want to help companies bring these therapies to patients as quickly as possible, which, even after FDA approval, will not happen without adequate health plan coverage."

Specific areas covered in this document include:

"One of ARM's goals is to provide our members with the tools they need to succeed in the marketplace, and this resource will certainly provide a lot of reimbursement assistance. We hear over and over from companies and their investors that this is a topic on which they are seeking guidance," said Michael Werner, Executive Director of ARM. "We are also developing additional tools to help regenerative medicine companies with the development and commercialization of their products."

The Regenerative Medicine Reimbursement Guide is available online at http://alliancerm.org/reimbursement

About The Alliance for Regenerative MedicineThe Alliance for Regenerative Medicine (ARM) is a Washington, DC-based multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, DC to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.

See the original post:
Comprehensive Portfolio Prepared by the Alliance for Regenerative Medicine Guides Companies Through Reimbursement ...

SINGAPORE AND TORONTO, ONTARIO--(Marketwired - Oct 11, 2013) - 360ip and the Canadian Centre for Commercialization of Regenerative Medicine (CCRM) are signing a collaboration agreement to work together in a variety of areas, including developing a fund to invest in best-in-class regenerative medicine (RM) technologies and companies in Asia, Europe and North America.

"360ip has expertise in identifying, commercializing and monetizing intellectual property [IP] worldwide with a particular focus in Asia," explains Asashi Fujimori, SVP of 360ip and Representative Director of 360ip JAPAN. "CCRM has built up an excellent network of leading academic and industry partners in the RM field, and combined with our strengths and contacts, we expect great things to come from this partnership."

"It benefits Canada if CCRM is sourcing best-in-class RM IP from around the world and this affiliation opens the doors for CCRM to do just that," says Michael May, CEO of CCRM. "This fund is an exciting undertaking that will be good for the global community. I'm very pleased that CCRM's value has been recognized internationally and we look forward to collaborating with 360ip, a commercialization leader in the Asian market."

360ip JAPAN, a 360ip affiliate, provides technology commercialization, investment and fund management expertise across a variety of industries with a particular emphasis on the life sciences. 360ip JAPAN was recently selected by the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT) to serve as a Project Promoter under the STart-ups from Advanced Research and Technology (START) Program. 360ip JAPAN's area of focus for this program is regenerative medicine and it will work closely with CCRM to identify marketable IP.

Representatives from 360ip and CCRM are currently attending Bio Japan 2013 in Yokohama, Japan, from October 9-11 http://www.ics-expo.jp/biojapan/seminar_schedule.html. Dr. Allison Brown, Director of Commercialization for CCRM, presented "Overview of Canada's Public-Private Partnership in Commercialization of Stem Cell Research - A Focus on Stem Cell-based Predictive Drug Screening" on Oct. 9th. For a copy of her presentation, contact CCRM.

About 360ip Pte Ltd ("360ip")

360ip is a global technology commercialization, investment and fund management company, headquartered in Singapore, with teams based throughout Asia and North America. 360ip includes an experienced group of operational, technical and financial professionals with a strong track record in technology commercialization and investment in high-growth companies.

360ip was jointly established by Battelle Memorial Institute ("Battelle"), the world's largest nonprofit R&D and commercialization organization, and Battelle Ventures, the venture capital firm affiliated with Battelle. Battelle, which began operations in 1929, generates more than US$6.0 billion in consolidated annual revenue, oversees more than 22,000 employees worldwide and has extensive life science-related capabilities and facilities. Battelle Ventures - whose sole limited partner is Battelle - and its affiliate fund, Innovation Valley Partners, have a combined US$255 million under management. Development Bank of Japan is also a shareholder of 360ip, and the companies have entered into a strategic collaboration in Japan.

About the Centre for Commercialization of Regenerative Medicine (CCRM)

CCRM, a Canadian not-for-profit organization funded by the Government of Canada's Networks of Centres of Excellence program and six academic partners, supports the development of technologies that accelerate the commercialization of stem cell- and biomaterials-based technologies and therapies. A network of academics, industry and entrepreneurs, CCRM aims to translate scientific discoveries into marketable products for patients. CCRM launched in Toronto's Discovery District on June 14, 2011. CCRM is hosted by the University of Toronto.

Continued here:
360ip and CCRM Join Forces to Source Best IP in Regenerative Medicine

09.10.2013 - (idw) Translational Centre for Regenerative Medicine (TRM) Leipzig

The World Conference on Regenerative Medicine will be held in Leipzig from 23 25 October 2013. Around 1,000 international researchers, medical practitioners and company representatives will take part in the event, exchanging views on new stem cell technologies, artificial tissue engineering, biomaterials, diagnostics and molecular bases of regeneration. For further details and the final scientific programme, please visit the conference homepage http://www.wcrm-leipzig.com. Over 40 renowned speakers will present their latest research projects across the three-day event. Two of these scientists are Li Qian, McAllister Heart Institute, USA, and Marius Wernig, Stanford School of Medicine, USA, whose research focuses on the direct reprogramming of cells.

At the end of 2012, Shinya Yamanaka, Japan, and John Gurdon, UK, received the Nobel Prize in Medicine for the reprogramming of differentiated cells to induced pluripotent stem cells (iPS). Similar to embryonic stem cells, iPS cells are able to redevelop into any type of cell in the body. Based on this technology, other research groups have now managed to directly transform cells - without having to go via iPS cells, a path which had proven to be laborious and ineffective. This direct form of cell reprogramming is one of the current topics being addressed at the World Conference on Regenerative Medicine.

The World Conference on Regenerative Medicine is organised every two years by the Fraunhofer Institute for Cell Therapy and Immunology and the Translational Centre for Regenerative Medicine at the University of Leipzig.

Contact

Maria Garz | Press and Public Relations Translational Centre for Regenerative Medicine (TRM) Leipzig | Leipzig University

Jens Augustin | Head of Press and Public Relations Fraunhofer Institute for Cell Therapy and Immunology IZI

Tel.: +49 341 35536-9320 E-Mail: press@wcrm-leipzig.com Weitere Informationen:http://www.wcrm-leipzig.com - Conference Homepagehttp://www.izi.fraunhofer.de - Fraunhofer IZI homepage / Organizerhttp://www.trm.uni-leipzig.de - TRM Leipzig homepage / Organizer

View original post here:
International Conference on Regenerative Medicine in Leipzig

Sep. 30, 2013 Mayo Clinic researchers are part of the second phase of a national consortium that focuses on developing innovative medical treatments for wounded veterans. Mayos role will emphasize peripheral nerve regeneration. Mayos principal investigator is Anthony Windebank, M.D., a neurologist and deputy director for discovery in the Mayo Clinic Center for Regenerative Medicine. Other organizations will focus on head and face trauma, burns, transplants and other conditions.

The opportunity to work together with a multidisciplinary, multi-institutional team that will create new therapies for our injured service members is a privilege, and we are proud that Mayo Clinic will be able to make a contribution to this effort, says Dr. Windebank. Other Mayo investigators include Michael Yaszemski, M.D., Ph.D., biomedical engineering and orthopedics; Allen Bishop, M.D., orthopedics; Alexander Shin, M.D., orthopedics; and Robert Spinner, M.D., neurologic surgery.

The consortium -- the Armed Forces Institute of Regenerative Medicine (AFIRM) -- is part of a national effort created to address the health care challenges of severely injured veterans returning from Afghanistan and Iraq. It is funded by the Army Medical Research and Materiel Command, in conjunction with the Office of Naval Research and the National Institutes of Health.

The first phase of AFIRM, which began in 2008, resulted in clinical studies of face transplantation, minimally invasive surgery for craniofacial injuries, a lower-dose anti-rejection regimen after kidney transplantation, scar reduction treatments, fat grafting for reconstructive surgery and new treatments for burns. The second phase (AFIRM-II) is a five-year, $75 million project and will focus on developing clinical therapies.

AFIRM-II will build on the efforts of the first five years, using regenerative medicine to develop new products and therapies to repair battlefield injuries. Regenerative medicine employs cell therapy (including stem cells), tissue and biomaterials engineering, and transplants to enable the body to repair, replace, restore and regenerate damaged tissues and organs. It will accelerate the rate at which biomaterials and technologies are converted into therapies to restore lost tissue and function. These products and therapies also will serve civilian trauma and burn patients.

The Mayo Clinic Center for Regenerative Medicine is honored to partner in this national effort poised to transform the care of severely wounded veterans. Advances in regenerative technologies promise unprecedented benefits for patients, their families and society, says Andre Terzic, M.D., Ph.D., the Michael S. and Mary Sue Shannon Family Director, Center for Regenerative Medicine, and Marriott Family Professor of Cardiovascular Diseases Research at Mayo Clinic.

See more here:
Researchers apply regenerative medicine to battlefield injuries

Public release date: 30-Sep-2013 [ | E-mail | Share ]

Contact: Jennifer Schutz newsbureau@mayo.edu 507-284-5005 Mayo Clinic

ROCHESTER, Minn. -- Mayo Clinic researchers are part of the second phase of a national consortium that focuses on developing innovative medical treatments for wounded veterans. Mayo's role will emphasize peripheral nerve regeneration. Mayo's principal investigator is Anthony Windebank, M.D., a neurologist and deputy director for discovery in the Mayo Clinic Center for Regenerative Medicine. Other organizations will focus on head and face trauma, burns, transplants and other conditions.

"The opportunity to work together with a multidisciplinary, multi-institutional team that will create new therapies for our injured service members is a privilege, and we are proud that Mayo Clinic will be able to make a contribution to this effort," says Dr. Windebank. Other Mayo investigators include Michael Yaszemski, M.D., Ph.D., biomedical engineering and orthopedics; Allen Bishop, M.D., orthopedics; Alexander Shin, M.D., orthopedics; and Robert Spinner, M.D., neurologic surgery.

The consortium -- the Armed Forces Institute of Regenerative Medicine (AFIRM) -- is part of a national effort created to address the health care challenges of severely injured veterans returning from Afghanistan and Iraq. It is funded by the Army Medical Research and Materiel Command, in conjunction with the Office of Naval Research and the National Institutes of Health.

The first phase of AFIRM, which began in 2008, resulted in clinical studies of face transplantation, minimally invasive surgery for craniofacial injuries, a lower-dose anti-rejection regimen after kidney transplantation, scar reduction treatments, fat grafting for reconstructive surgery and new treatments for burns. The second phase (AFIRM-II) is a five-year, $75 million project and will focus on developing clinical therapies.

AFIRM-II will build on the efforts of the first five years, using regenerative medicine to develop new products and therapies to repair battlefield injuries. Regenerative medicine employs cell therapy (including stem cells), tissue and biomaterials engineering, and transplants to enable the body to repair, replace, restore and regenerate damaged tissues and organs. It will accelerate the rate at which biomaterials and technologies are converted into therapies to restore lost tissue and function. These products and therapies also will serve civilian trauma and burn patients.

"The Mayo Clinic Center for Regenerative Medicine is honored to partner in this national effort poised to transform the care of severely wounded veterans. Advances in regenerative technologies promise unprecedented benefits for patients, their families and society," says Andre Terzic, M.D., Ph.D., the Michael S. and Mary Sue Shannon Family Director, Center for Regenerative Medicine, and Marriott Family Professor of Cardiovascular Diseases Research at Mayo Clinic.

The core academic partners of AFIRM-II are Mayo Clinic; Brigham and Women's Hospital; Case Western Reserve University; Cleveland Clinic; Georgia Institute of Technology; Jewish Hospital; Johns Hopkins University; Livionex Inc.; Massachusetts General Hospital; New York University School of Medicine; Northwestern University; Oregon Health & Science University; Radboud University Medical Center; Research Foundation of SUNY; Rice University; Stanford University School of Medicine; Rutgers, The State University of New Jersey; Southwest Research Institute, Stratatech Corporation; The Ohio State University College of Medicine; Tufts University; University of California, Los Angeles; University of Cincinnati, University of Connecticut; University of Florida; University of Louisville School of Medicine; University of Maryland School of Medicine, University of Michigan; University of Pittsburgh; UW Medicine; Vanderbilt University Medical Center; and Wake Forest University School of Medicine (Wake Forest Baptist Medical Center). These core partners are supported by a large number of industrial collaborators and participating health care companies that have expressed an interest in the commercialization of new products and therapies emerging from AFIRM's research program.

###

Here is the original post:
Mayo Clinic researchers apply regenerative medicine to battlefield injuries

ROCKVILLE, Md., Sept.26, 2013 /PRNewswire/ --Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO, Richard Garr, will present at the Stem Cells & Regenerative Medicine Congress, on Monday, September 30 at 12:00 PM at the Hyatt Regency in Cambridge, MA (http://www.terrapinn.com/2013/stem-cells-usa-regenerative-medicine/index.stm). Mr. Garr will give an overview of Neuralstem's ongoing trial testing NSI-566 stem cells in amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), now in Phase II, as well as a clinical progress update.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

In a separate presentation, ALS patient, Ted Harada, who received transplants in both his lumbar and cervical spinal regions in Phase I of the Neuralstem trial, will talk about his experience as a patient on Monday, September 30, at 9:00 AM.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem's NSI-566 spinal cord-derived stem cell therapy is in an FDA-approved Phase II clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy.

In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury andischemic stroke. The company has received FDA approval to commence a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions. The company is conducting a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD).Additional indications could include traumatic brain injury (TBI), Alzheimer's disease, and post-traumatic stress disorder (PTSD).

For more information, please visit http://www.neuralstem.com or connect with us on Twitter, Facebook and LinkedIn

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2012 and the Form 10-Q for the period ended June 30, 2013.

Continued here:
Neuralstem CEO To Present At Stem Cells & Regenerative Medicine Congress

Nurturing the science behind regenerative medicine
Speakers Dr Paul Fairchild, Oxford Stem Cell Institute Further Information October 2008: Showcase: Oxford Stem Cell Institute - Dr Paul Fairchild Oxford Mart...

By: 21school

Read more:
Nurturing the science behind regenerative medicine - Video